NCT06015724View on ClinicalTrials.gov

Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2027

Conditions
Pancreatic Ductal AdenocarcinomaRefractory Non-Small Cell Lung Cancer
Interventions
DRUG

Daratumumab

anti-CD38 monoclonal antibody (mAb)

BIOLOGICAL

KRAS vaccine

Stimulon QS-21 and Targovax TG01

DRUG

Nivolumab

anti-PD-1 (programmed cell death protein 1) monoclonal antibody (mAb)

Trial Locations (2)

20007

RECRUITING

Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.

07601

RECRUITING

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Janssen, LP

INDUSTRY

collaborator

Targovax ASA

INDUSTRY

lead

Georgetown University

OTHER

NCT06015724 - Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter